B
Broad Institute
A unique, collaborative community pioneering a new model of biomedical science
About Broad Institute
The Broad Institute is a pioneering biomedical and genomic research center that focuses on understanding and treating diseases through cutting-edge science. It operates in the healthcare and biotechnology market, serving a diverse range of clients including academic researchers, pharmaceutical companies, healthcare providers, and educational institutions. The Institute's primary mission is to advance the understanding of human biology and disease, with a particular emphasis on genetic research.
Read full description
Broad Institute's business model is built around collaborative research and innovation. It brings together scientists from various disciplines to work on large-scale projects that aim to uncover the genetic basis of diseases such as schizophrenia, bipolar disorder, immune disorders, and cardiovascular diseases. The Institute also develops educational tools and resources, such as pandemic simulation apps and STEM classroom materials, which are used by schools and educators nationwide.
Revenue for the Broad Institute comes from a mix of government grants, private donations, partnerships with pharmaceutical companies, and licensing of its research findings and technologies. By publishing scientific papers and providing access to key datasets and computational tools, the Institute not only contributes to the scientific community but also generates income through intellectual property and collaborative agreements.
In summary, the Broad Institute is a leader in biomedical research, focusing on genetic and genomic studies to improve disease diagnosis and treatment. It serves a wide range of clients in the healthcare and education sectors, operating on a collaborative research model that generates revenue through grants, donations, partnerships, and intellectual property.
At a glance
- Founded
- 2003
- Headquarters
- Cambridge, United States
- Employees
- 3,199
- Open positions
- 42
- Dealroom signal
- 65.7/100
- Sector
- Biotechnology, Biomedical, Horizon Europe, research institute, science-based
- Investment activity
- 16 companies, latest Jan 2022
- Capital deployed
- $0
- Preferred round
- SPINOUT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Aug 2020 | — | — | Alzheimer's Foundation of America | — |
| LATE VCOther financing | Oct 2017 | $50M | $200M | Deerfield | ↗ |
Open positions
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Delphia TherapeuticsCambridge, United StatesDelphia is pioneering activation lethality - a next-generation precision medicine approach that targets cancer's surprising vulnerability to oncogene overactivation
$268Mvaluation
Moonwalk BiosciencesSouth San Francisco, United StatesFocused on precise epigenetic solutions, mapping cellular states at the genome level for innovative therapeutics
$182Mvaluation
StellaromicsNatick, United StatesA biomedical research company with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue
$320Mvaluation
Aera TherapeuticsBoston, United StatesAera is developing a new class of genetic medicines based on its proprietary crispr-based platform
$232Mvaluation
Signet TherapeuticsShenzhen, ChinaDevelops targeted cancer drugs using disease models and AI to improve patients' lives
$55Mvaluation
Kojin TherapeuticsCambridge, United StatesDeveloping transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology
$121Mvaluation
Civetta TherapeuticsCambridge, United StatesCivetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains
→
Immunitas TherapeuticsCambridge, United StatesDeveloping targeted therapeutics for patients with challenging, complex cancers by unlocking human immunology using novel single cell analyses
$232Mvaluation
Sherlock BiosciencesCambridge, United StatesSherlock Biosciences is an engineering biology company
$320Mvaluation
Fauna BioBerkeley, United StatesFauna Bio is a biotechnology company leveraging the science of hibernation to improve healthcare for humans
$36Mvaluation
Celsius TherapeuticsCambridge, United StatesSingle-cell RNA sequencing and genomic analysis
$250Mvaluation
Arbor BiotechnologiesCambridge, United StatesDiverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability
$1.1Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Klarman Family Foundation
Edythe Broad
Eli Broad
Alzheimer's Foundation of America
Series B and later1 investor entered at this stage
Deerfield
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Broad Institute on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Broad Institute’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.